Related Experiment Videos
Moxalactam therapy of bacterial meningitis in adults
Abstract:
The therapeutic efficacy and attainable cerebrospinal fluid (CSF) concentrations of moxalactam, administered by intravenous drip in a dose of 2 g every 4 to 8 h, were evaluated in seven adult patients with bacterial meningitis. Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter calcoaceticus var. anitratus, each caused infection in four patients, whereas Escherichia coli was the cause of infection in the other three patients. The mean moxalactam concentration in CSF was 14.7 mug/ml (range, 4.7 to 38 mug/ml) in the lumbar samples and 12.1 mug/ml (range, 4.4 to 27 mug/ml) in the ventricular samples. Depending on the time after antibiotic administration, the ratio of CSF to serum concentrations varied from 6.6 to 160%. Satisfactory improvement and negative CSF cultures were initially noted in all seven patients. Six patients were ultimately cured, and the death of the patient with Pseudomonas meningitis could not be clearly attributed to uncontrolled infection.
Insights
Moxalactam effectively treated bacterial meningitis, achieving significant cerebrospinal fluid (CSF) concentrations in patients. Most patients showed improvement, with six cured, demonstrating moxalactam
Area of Science:
- Pharmacology
- Infectious Diseases
- Neuroscience
Background:
- Bacterial meningitis remains a critical global health concern.
- Effective antibiotic penetration into the cerebrospinal fluid (CSF) is crucial for treatment success.
- Moxalactam is a novel beta-lactam antibiotic with potential utility against meningitis pathogens.
Purpose of the Study:
- To evaluate the therapeutic efficacy of moxalactam in treating bacterial meningitis.
- To determine achievable cerebrospinal fluid (CSF) concentrations of moxalactam.
- To assess the safety and effectiveness of moxalactam in adult patients.
Main Methods:
- Seven adult patients diagnosed with bacterial meningitis were enrolled.
- Moxalactam was administered intravenously at a dose of 2 g every 4 to 8 hours.
- Cerebrospinal fluid (CSF) and serum concentrations of moxalactam were measured.
- Clinical outcomes and CSF cultures were monitored throughout the study.
Main Results:
- Moxalactam achieved mean CSF concentrations of 14.7 µg/ml (lumbar) and 12.1 µg/ml (ventricular).
- CSF to serum concentration ratios ranged from 6.6% to 160%, indicating good penetration.
- All seven patients initially showed satisfactory improvement with negative CSF cultures.
- Six out of seven patients were ultimately cured; one death was not clearly linked to uncontrolled infection.
Conclusions:
- Moxalactam demonstrates therapeutic efficacy in treating bacterial meningitis.
- The antibiotic achieves favorable concentrations within the cerebrospinal fluid.
- Moxalactam is a promising treatment option for bacterial meningitis, warranting further investigation.